Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD, Caroline Farrington, PhD, Vicki L. Gordon, BS, Shekhar Saha, PhD, Christopher Morris, BS, Krista M. Isaac, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Goutham Narla, MD PhD, Michael J. Weber, PhD

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-138954

Published: 2020

Journal Articles

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Craig A. Portell, MD, Nolan A Wages, PhD, Brad S. Kahl, MD, Lihua E Budde, MD PhD, Robert W. Chen, MD, Jonathon B. Cohen, MDMS, Gina Petroni, PhD, Michael E. Williams, MD

Blood (2019) 134 (Supplement_1): 1535.

https://doi.org/10.1182/blood-2019-128788

Published: 2019

Journal Articles

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Konrad J. Cios, BSc (2019), Vicki L. Gordon, BSc, Puja C. Arora, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2018-99-119521

Published: 2018

Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2018-99-116759

Published: 2018

Journal Articles

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Puja C. Arora, MD, Victor M. Orellana-Noia, MD, Abeer Alfaraj, MBBS, Wenzinger Christopher, MD, Sandra Monson, PhD, Gina Petroni, PhD, Craig A. Portell, MD, Michael E. Williams, MD

Blood (2018) 132 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2018-99-117651

Published: 2018

Journal Articles

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L Gordon, BS, Brian J Capaldo, PhD, Stefan Bekiranov, PhD, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2016) 128 (22): 754.

https://doi.org/10.1182/blood.V128.22.754.754

Published: 2016

Journal Articles

Major Bleeding with Ibrutinib: More Than Expected

Paul R Kunk, MD, Joesph Mock, MD, Michael E. Devitt, MD, Surabhi Palkimas, Pharm D., Jeremy Sen, Pharm D., Craig A. Portell, MD, Michael E. Williams, MD

Blood (2016) 128 (22): 3229.

https://doi.org/10.1182/blood.V128.22.3229.3229

Published: 2016

Journal Articles

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Craig A. Portell, MD, Robert W Chen, MD, Nolan Wages, PhD, Jonathon B. Cohen, MD, Michael J. Weber, PhD, Gina Petroni, PhD, Brad S. Kahl, MD, Michael E Williams, MD

Blood (2016) 128 (22): 2958.

https://doi.org/10.1182/blood.V128.22.2958.2958

Published: 2016

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

Journal Articles

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Kallesh D. Jayappa, PhD, Craig A. Portell, MD, Vicki Gordon, B.S., Michael E. Williams, MD, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael J. Weber, PhD

Blood (2015) 126 (23): 448.

https://doi.org/10.1182/blood.V126.23.448.448

Published: 2015

Journal Articles

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Blood (2015) 126 (23): 3961.

https://doi.org/10.1182/blood.V126.23.3961.3961

Published: 2015

Journal Articles

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Blood (2014) 124 (21): 4453.

https://doi.org/10.1182/blood.V124.21.4453.4453

Published: 2014

Journal Articles

First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents

Mark R. Green, MD, Michael E. Williams, MD, Joanne Willey, RN, Arden Buettner, Douglas Neely, Maria Lankford

Blood (2014) 124 (21): 4676.

https://doi.org/10.1182/blood.V124.21.4676.4676

Published: 2014

Journal Articles

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Craig A. Portell, MD, Mark Axelrod, PhD, L. Kyle Brett, MD, Vicki L Gordon, BS, Brian Capaldo, Jeffrey C Xing, Stephan Bekiranov, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2014) 124 (21): 509.

https://doi.org/10.1182/blood.V124.21.509.509

Published: 2014

Journal Articles

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Andre Goy, MD, Michael E. Williams, MD, ScM, Sevgi Kalayoglu Besisik, MD, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M Rowe, MD, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, Lei Zhang, Sherri Cicero, Tommy Fu, Carla Heise, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 3057.

https://doi.org/10.1182/blood.V122.21.3057.3057

Published: 2013

Journal Articles

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

L. Kyle Brett, MD, Mark Axelrod, PhD, Zhishuo Ou, MD, Liang Zhang, MD, PhD, Vicki Gordon, BS, Elyse R Lopez, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Michael J. Weber, PhD, Michael E. Williams, MD, ScM, Michael Wang, MD

Blood (2013) 122 (21): 3080.

https://doi.org/10.1182/blood.V122.21.3080.3080

Published: 2013

Journal Articles

First-Line Prescribing Preferences of American Hematology-Oncology Physicians for Patients with CLL: Impact of Age, Co-Morbidities, and Tempo of Disease

Mark R. Green, MD, Michael E. Williams, MD, Joanne Willey, RN, Mitchell Scharf, Douglas Neely, Michael G. Heckman, MS, James M. Foran, MD, FRCPC

Blood (2012) 120 (21): 4608.

https://doi.org/10.1182/blood.V120.21.4608.4608

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Luhua Wang, MD, Peter Martin, MD, Kristie A. Blum, MD, Brad S. Kahl, MD, Lauren S. Maeda, MD, Ranjana Advani, MD, Michael E. Williams, MD, Simon Rule, MD, Sara Rodriguez, Ching-Fai Pang, PhD, Eric Hedrick, MD, Andre Goy, MD

Blood (2011) 118 (21): 442.

https://doi.org/10.1182/blood.V118.21.442.442

Published: 2011

Journal Articles

Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) by American Hematology-Oncology Providers (AHOP's): Changes in 1st-Line Treatment Preferences Over Time in Relation to Cytogenetics & Survival Data From Randomized Studies (2006–2010),

James M. Foran, MD, FRCPC, Michael G. Heckman, MS, Michael E. Williams, MD, Joanne Willey, RN, Mark R. Green, MD

Blood (2011) 118 (21): 3816.

https://doi.org/10.1182/blood.V118.21.3816.3816

Published: 2011

Journal Articles

Immunologically Targeting the Leukaemia Phosphoproteome

Hugo De La Peña, MD, PhD, Postdoc, Thomas Butler, Hsing-Wen Huang, Toral Jakhira, Chung-Yang Joseph, Sarah Penny, David Millar, Charles Craddock, Guy Pratt, Michael E. Williams, MD, Donald F Hunt, Victor H Engelhard, Mark Cobbold, PI

Blood (2010) 116 (21): 1016.

https://doi.org/10.1182/blood.V116.21.1016.1016

Published: 2010

NARROW

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Major Bleeding with Ibrutinib: More Than Expected

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

First-Line Prescribing Preferences of American Hematology-Oncology Physicians for Patients with CLL: Impact of Age, Co-Morbidities, and Tempo of Disease

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) by American Hematology-Oncology Providers (AHOP's): Changes in 1st-Line Treatment Preferences Over Time in Relation to Cytogenetics & Survival Data From Randomized Studies (2006–2010),

Immunologically Targeting the Leukaemia Phosphoproteome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only